Long-term survival of stage I multiple myeloma given chemotherapy just after diagnosis or at progression of the disease: a multicentre randomized study by Riccardi, A et al.
Patients with stage I (Durie and Salmon, 1975) multiple myeloma
(MM) represent about 20% of patients with this disease (Jagannath
et al, 1993; Bjorkstrand et al, 1994; Cunningham et al, 1994;
Riccardi et al, 1994; Bensiger et al, 1996; Vesole et al, 1996).
Most of these patients have no symptoms and diagnosis is usually
due to a screening laboratory work-up revealing an increased
serum monoclonal component (MC) concentration (Riccardi et al,
1991).
Physicians are still faced with the treatment options for these
patients, i.e. as to whether starting chemotherapy as soon as diag-
nosis is made or delaying it until symptoms arise due to disease
progression. In fact, although some patients have stable disease for
years, a relevant number of them progress to overt symptomatic
MM within 12–24 months (Dimopoulous et al, 1993; Hjorth et al,
1993; Facon et al, 1995). Two randomized studies (Hjorth et al,
1993; Riccardi et al, 1994) have suggested that delaying treatment
does not influence survival, as in chronic lymphocytic leukaemia
(Dighiero et al, 1998), but these studies are biased by the low
number of enrolled patients and by the short follow-up.
We report the long-term survival results of 145 patients who
were randomized between receiving treatment with melphalan-
prednisone (MPH-P) just after diagnosis or at disease progression.
MATERIALS AND METHODS
Between January 1987 and March 1993, 145 previously untreated
stage I MM patients (Table 1) from 19 centres entered two consec-
utive multicenter protocols [MM87: between January 1987 and
March 1990 (Riccardi et al, 1994); MM90: between April 1990
and March 1993 (unpublished)], that were aimed at giving sepa-
rate randomized options for first-line and maintenance treatment
to patients with stage I, II and III MM. The protocols were
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Summary We conducted a randomized trial to evaluate whether melphalan-prednisone (MPH-P) treatment administered just after diagnosis
improves survival of stage I multiple myeloma (MM). Between January 1987 and March 1993, 145 consecutive previously untreated patients
with stage I MM were randomized between treatment with MPH-P (administered for 4 days every 6 weeks) just after diagnosis and treatment
only at disease progression. Survival was not influenced by MPH-P treatment either administered just after diagnosis or at disease
progression (64 vs 71 months respectively). Comparing the first with the second group the odds ratio of death is 1.17 (95% confidence interval
0.57–2.42; P = 0.64). Disease progression occurred within a year in about 50% of patients who were initially untreated. Response rate was
similar in both groups, but duration of response was shorter in patients who were treated at disease progression (48 vs 79 months, P = 0.044).
Patients actually treated at disease progression (34/70) survived shorter than those who had neither disease progression nor treatment
(56 vs > 92 months; P = 0.005). Starting MPH-P just after diagnosis does not improve survival and response rate in stage I MM, with respect
to deferring therapy until disease progression. However, patients with stage I MM randomized to have treatment delayed and who actually
progressed and were treated had shorter survival than those with stable disease and no treatment. Biologic or other disease features could
identify these subgroups of patients. © 2000 Cancer Research Campaign
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approved by the Clinical Research Review Board of the Internal
Medicine Department of the University of Pavia, and written
informed consent was obtained from each enrolled patient.
Both protocols randomized stage I MM between receiving
MPH-P just after diagnosis or at disease progression. The protocol
MM90 differs from protocol MM87 only in that interferon a-2b
was added to all phases of treatment in patients with stage II and
III, but not with stage I disease.
Diagnosis
Diagnosis of MM required the presence of at least two of the three
following features: (1) a serum and/or urine MC; (2) a bone
marrow plasma cell (BMPC) infiltration greater than 20%, as
evaluated on trephine BM biopsy (Riccardi et al, 1990); (3) the
presence of osteolytic lesions unexplained by other causes.
Other causes of increased marrow plasmacytosis and of
monoclonal gammopathy had to be carefully excluded before a
diagnosis of MM was made (Riccardi et al, 1994).
Randomizations and treatment
Upon admission, patients were staged according with Durie and
Salmon (1975). Stage I MM patients had to have all the following
features: Hb > 10 g dl–1, corrected serum calcium ≤ 12 mg dl–1,
normal bone skeletal X-ray or a single lytic lesion, serum lgG or
lgA < 5 or 3 g dl–1 respectively, and daily light chain excretion
< 4 g. Randomizations for both first-line and maintenance therapy
(Riccardi et al, 1994) were given by a Central Secretariat at the
Medicina Interna & Medical Oncology of University of Pavia.
Randomizations were attributed separately for each participating
centre from a computer-generated list, just after the name and the
affiliation of the patient were communicated by phone or fax.
In both MM87 and MM90 protocols, as first-line policy, stage I
MM were randomized, between being treated just after diagnosis
with MPH (0.21 mg kg–1 day–1 orally, days 1–4) and P (0.50 mg
kg–1 day–1 orally, days 1–10), given at 6-week intervals for 6
courses or receiving the same treatment at progression of the
disease.
Response was evaluated after 6 courses of MPH-P, according to
slightly modified (Riccardi et al, 1994) clinical criteria adopted by
the SECSG (Cohen et al, 1979).
Criteria were as follows: (a) reduction in MC; (b) decrease in
BMPC of at least 20% or return to less than 20%, as evaluated on
BM imprints before and after treatment; (c) a 2 g dl–1 rise in Hb
concentration in anaemic patients (Hb < 11 g dl–1) sustained for
more than 4 weeks; (d) return of serum calcium and blood urea
nitrogen (BUN) to normal values; (e) elevation of serum albumin
up to or greater than 3 g dl–1 in the absence of other causes of
hypoalbuminaemia; (f) absence of progression of skeletal lytic
lesions.
Complete response (CR) was a > 50% reduction in MC and a
response in more than half of the other parameters. Partial
response (PR) was a 25–50% reduction in MC and a response in
more than half of the other parameters. No response (NR) was the
no fulfillment of the above criteria for CR and PR. Progression
was a > 25% increase in MC and/or an increase in BMPC of at
least 20% and/or worsening of laboratory parameters (mainly
haemoglobin, serum calcium and BUN) and/or of skeletal lytic
lesions.
Patients who had CR or PR were randomized between receiving
additional courses of MPH-P until maximum reduction in MC
(i.e. the plateau phase) was achieved (Riccardi et al, 1994) and
then stopping all cytostatics until relapse, or continuing therapy
indefinitely until relapse, as a maintenance.
Patients who had response to MPH-P and then relapsed while
on no maintenance were retreated with MPH-P until second
relapse.
Patients who were resistant to MPH-P, those who had stable
disease after MPH-P and then progressed, those who relapsed
while on MPH-P maintenance, and those who had second relapse
after second MPH-P treatment were treated, as second-line
treatment, with the association of peptichemio (PTC; Istituto
Sieroterapico Milanese, Milan, 0.8 mg kg–1 day–1 by intravenous
(i.v.) infusion, days 1, 3 and 5), vincristine (VCR; 0.025 mg kg–1
day–1, maximal dose 2 mg, days 1 and 14) and P (0.4 mg kg–1
day–1, days 1–7) given every 28 days for 4 courses. Patients who
achieved response with this second-line treatment continued to be
treated with this schedule until relapse (Figure 3).
Follow-up
It has been detailed elsewhere (Riccardi et al, 1994). Briefly,
performance status, blood and 24-h urine laboratory parameters,
BM examination and skeletal X-rays were assessed at diagnosis
and repeated every 2–3 months throughout the induction period.
Then these examinations were repeated every 3–6 months or at
longer intervals, as needed from clinical indications.
Table 1 Main characteristics of patients with stage I multiple myeloma treated with melphalan-prednisone just after
diagnosis or at progression of the disease
Patients treated at Patients treated at disease
diagnosis progression
n % n % P
Patients 75 100 70 100 NS
M/F 46/29 61/39 34/36 49/51 NS
IgG/IgA 54/21 72/28 52/18 74/26 NS
K/L 45/30 60/40 41/29 59/41 NS
b2</> 4.0 mg dl–1 62/13 83/17 57/13 82/18 NS
BMPC% ≤ 10/10–20/ ³ 20% 6/26/43 8/35/57 5/34/31 7/49/44 NS
With one osteolysisa 17 23 18 26 NS
With symptoms 9 12 8 11 NS
aGiven radiotherapy.1256 A Riccardi et al
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Data collection
Information on the occurrence and on the duration of response
were obtained from the brochure records. Duration of response is
calculated from the end of successful induction therapy until
relapse, and censored were surviving patients who did not have a
relapse during the follow-up (patients who died before relapse
were considered as events). Survival is the time from randomiza-
tion to death, as obtained from the brochure records or death
certificate based search. Causes of death were divided into those
related and those unambiguosly unrelated to MM.
Statistical analysis
The statistical analysis was carried out on an intention-to-treat
basis. Features that could be prognostic for survival were searched
by both the univariate analysis and the Cox multivariate regression
analysis of the clinical, laboratory and radiologic parameters listed
in Tables 1 and 2. The Cox analysis also included whether the
patient started the treatment or not.
Differences in the response rate among the different groups of
patients were tested by the contingency table mc2 test. Survival
analysis was based on Kaplan–Meier estimates, the log-rank test
and the Cox regression model. All P are two-sided and adjusted for
repeated analysis.
RESULTS
The results of this study are reported in Tables 1–6 and Figures 1
and 2. Overall, 145 patients entered the study. Seventy-five of
them (median age = 69 years, range 39–88) were treated just after
diagnosis and 70 (median age = 68 years, range 33–85) at disease
progression. The slight imbalance between the two arms is due to
the fact that randomization was separately done for each centre
and that two patients randomized to have therapy delayed were
later found to be stage II MM. All patients who were randomized
to immediate or delayed treatment actually followed the assigned
randomization. The main clinical and laboratory characteristics of
the two groups were similar and are detailed in Tables 1 and 2.
Eighty-eight per cent of patients had no disease-related symp-
toms, and the diagnosis was from the chance finding of a serum
MC on routine haematochemical tests. Nine per cent of patients
complained of bone pain at the site of the osteolyse, most often
located in the spine, chest and pelvis. Patients with symptomatic or
asymptomatic osteolysis were given radiotherapy (Table 1). Three
Table 2 Additional laboratory characteristics of patients with stage I multiple myeloma treated with melphalan-prednisone just after diagnosis or at progression
of the disease
Parameter Patients treated at Patients treated at disease
diagnosis progression
Median Range Median Range P
ESR (mm 1st h) 47.0 4–124 40.0 1–130 NS
Hb (g dl–1) 12.8 9.3–15.6 13.3 10.7–17.3 NS
WBC (´109 l–1) 6.1 2.8–20.6 6.3 3.3–26 NS
PLT (´109 l–1) 227.0 118–479 231.0 100–429 NS
Creatinine (mg dl–1) 1.0 0.6–2.1 0.9 0.6–1.9 NS
Serum albumin (g dl–1) 4.1 2.6–5.3 4.2 2.1–5.2 NS
Serum MC (g dl–1) 2.2 0.5–4.6 1.9 0.5–3.3 NS
Normal Ig (%) 0.52 0.08–2.8 0.58 0.02–1.7 NS
Alkaline phosphatase (U dl–1) 137.0 24–302 134.0 21–317 NS
Uric acid (mg dl–1) 5.2 2.8–10 5.0 1.6–8.7 NS
S-Ca2+ (mg dl–1) 9.2 8.0–11.8 9.4 8.4–10.9 NS
U-Ca2+ (mg 24 h–1) 8.5 0.08–42.4 11.4 0.04–227 NS
BJ proteinuria (g 24 h–1) 1.28 0.1–11 0.9 0.1–10 NS
Table 3 Stage I MM patients: response to melphalan-prednisone (MPH-P)
according with randomization
Patients Patients
treated at treated at
diagnosis disease P
progression
Evaluable/entered patients 75/75 34/34 –
Overall response, n (%) 30 (40) 19 (55) NS
Complete response, n (%) 8 (11) 5 (15) NS
Partial response, n (%) 22 (29) 14 (41) NS
Stable disease, n (%) 40 (53) 12 (35) NS
Progressive disease, n (%) 5 (7) 3 (9) NS
Median duration of responseb, months 79 48 0.044
aEvaluable/entered patients = patients who were evaluable for response over
those who received MPH-P; bpatients who had complete or partial response
after MPH-P treatment.
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Figure 1 Survival of patients with stage I multiple myeloma according to
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per cent of patients complained of modest weakness and/or fatigue
during the last 6 months.
At the time of this analysis (March 1998), 138 patients have
completed follow-up and are evaluable for both response and
survival. Seven patients (three randomized to being treated just
after diagnosis and four at disease progression) have been lost to
follow-up after a period of 45 months (range 18–72) and were
evaluable only for first response.
Of the 138 fully evaluable patients, 77 (56%) have died. The
median follow-up of all patients is 65 months and that of living
patients is 93 months (range 60–139).
Control of the disease
In the 75 patients treated with MPH-P just after diagnosis, the
overall response rate was 40% and the median duration of first
response was 79 months (Table 3). No patient fulfilled the criteria
for response without receiving treatment.
Thirty-four (48%) of the 70 patients who were randomized to
have delayed treatment needed MPH-P because of disease
progression. The median time to progression was 13 months
(range 3–91). Treatment was required within 12 months in 16 out
of 34 patients, between 13 and 36 months in 12 patients, and later
in six patients.
Causes of disease progression and of starting treatment was a
sustained, although asyptomatic, increase in MC in 12 patients, the
appearance of a new and/or the enlargement of a preexisting bone
lesion in 11 patients (without MC increase in two patients), the
occurrence of anaemia (Hb < 10 g dl–1) in nine patients (without
MC increase in three patients), hypercalcaemia in one patient and
renal failure in one patient (both with MC increase). In the three
patients with disease progression diagnosed as due to isolated
anaemia, the BMPC% had risen by 12–18%. Following progres-
sion, 19 patients still had stage I disease, while 12 entered stage II
and three stage III disease. Two patients with worsening bone
disease had vertebral compression fractures and received either
chemo- and radiotherapy.
Overall response rate was 55% and the median duration of first
response was 48 months (P = 0.044 with respect to response dura-
tion in patients treated just after diagnosis) (Table 3).
Among the 49 patients who responded to MPH-P a second
response to this therapy was seen in eight (39%) of the 25 patients
randomized to stop treatment until relapse.
A response to PTC-VCR-P was seen in 27% of the 72 evaluable
patients who either progressed while on first MPH-P therapy
Table 4 Patients with stage I multiple myeloma who were randomized to be treated with melphalan-prednisone
(MPH-P) at disease progression: main characteristics of patients who had and did not have disease progression and
treatment
Patients with disease Patients without disease
progression and treatment progression and treatment
n % n % P
Patients 34 100 36 100 NS
M/F 16/18 47/53 18/18 50/50 NS
IgG/IgA 24/10 71/29 28/8 78/22 NS
K/L 21/13 62/38 20/16 56/44 NS
b2 </> 4.0 mg dl–1 26/8 76/24 32/4 89/11 NS
With one osteolysis 8 24 10 28 NS
BMPC% ≤ 10/10–20/³20% 2/15/17 7/44/49 3/19/14 7/54/39 NS
With symptoms 4 12 5 15 NS
Table 5 Additional laboratory characteristics of patients with stage I multiple myeloma treated with melphalan-prednisone at disease progression and of
patients who did not have disease progression and treatment
Parameter Patients with disease Patients with neither
progression and treatment disease progression nor
treatment
Median Range Median Range P
ESR (mm 1st h) 56.0 5–120 33.0 1–130 NS
Hb (g dl–1) 13.3 10.7–17 13.7 10.9–17.3 NS
WBC (´109 l–1) 5.7 3.3–10.7 6.8 3.6–26 0.01
PLT (´109 l–1) 221.0 154–429 243.0 100–415 NS
Creatinine (mg dl–1) 0.9 0.7–1.9 0.9 0.6–1.3 NS
Serum albumin (g dl–1) 4.3 3.4–5.2 4.1 2.1–5.2 NS
Serum MC (g dl–1) 2.1 0.6–3.3 1.9 0.5–3.2 0.04
Normal Ig (%) 0.48 0.1–1.4 0.59 0.02–1.7 NS
Alkaline phosphatase (U dl–1) 135.0 21–317 134.0 70–286 NS
Uric acid (mg dl–1) 5.0 1.6–8.7 5.2 3.0–8.7 NS
S-Ca2+ (mg dl–1) 9.5 8.6–10.4 9.4 8.4–10.9 NS
U-Ca2+ (mg 24 h–1) 11.4 0.14–148 12.5 0.04–227 NS
BJ proteinuria (g 24 h–1) 0.5 0.25–10 0.9 0.1–10 NS1258 A Riccardi et al
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(five patients), had stable disease after MPH-P and then
progressed (38 patients), relapsed while on MPH-P maintenance
(23 patients), or had second relapse after second MPH-P treatment
(six patients).
Survival duration
For all stage I MM patients, median survival was 69 months and
not influenced by the type of initial randomization, i.e. starting
MPH-P just after diagnosis (64 months) or at progression of the
disease (71 months) (Figure 1). Response duration was indepen-
dent on response to MPH-P. Comparing the first with the second
group the odds ratio of death is 1.17 (95% confidence interval
0.57–2.42; P = 0.64).
Median survival was similar in 35 patients with (63 months) and
103 without osteolyses (59 months). Median survival was 47 and
81 months (P = ns) for the 17 patients with osteolyses treated just
after diagnosis and for the 18 patients with osteolyses treated at
disease progression respectively. The two patients who had verte-
bral compression while untreated survived 68 and 71 months.
No prognostic feature (Tables 1 and 2) for survival was found
by both the univariate and Cox regression analysis.
Among patients randomized to have treatment delayed, those
who had disease progression and were treated fared worse (median
survival = 56 months) than those who had no disease progression
and are still untreated (median survival > 92 months) (P = 0.005)
(Figure 2). Median age was similar in these two sub-groups (69
(range 39–88) and 67 (range 38–78) years respectively) and no
major clinical and/or laboratory difference was found between
them, except that patients who had disease progression tended to
have lower WBC count and higher MC levels (Tables 4 and 5).
The Cox multivariate analysis failed to add further information.
Causes of death
Causes of death were assessable with certainty in 48 of the 76
patients who died. There were no differences in causes of death
between patients randomized to being treated just after diagnosis
or at progression of the disease (Table 6).
DISCUSSION
The analysis of stage I MM patients included into the protocols
MM87 and MM90 indicates that deferring treatment is a reason-
able alternative to immediate chemotherapy. In fact, the presented
long-term survival data (the median follow-up for living patients is
93 months) indicate that starting MPH-P just after diagnosis does
not prolong long-term survival, with respect to starting treatment
at disease progression.
These data confirm those from two other randomized studies
(Hjorth et al, 1993; Riccardi et al, 1994) that, however, included a
more limited number of cases (50 and 74 respectively) with a
shorter follow-up (the median follow-up for living patients was 48
and 51 months respectively). With respect to the study of Hjorth et
al (1993), where patients with lytic bone disease were excluded,
some of our stage I MM had an osteolyse, but this did not influ-
ence survival, irrespective of time of starting therapy. Also, causes
of death were similar and unrelated to time of therapy.
The advantage of delaying treatment in all stage I MM is of
avoiding the MPH-induced myelosuppression and the necessity of
closing follow-up in patients for whom there is no curative
therapy. Theoretically, bone marrow transplantation (BMT) may
cure them, but a number of factors limits its use. On one hand,
young age and a good initial response to conventional
Table 6 Causes of death of patients with multiple myeloma (MM) who were
randomized to being treated just after diagnosis or at progression of the
disease
Patients treated Patients treated
at diagnosis at disease
progression
Patients who died, no 41 35
Patients whose cause of death is 25 23
known, n
Causes related to MM, n (%) 19 (76) 16 (70)
Infections, n 78
Renal insufficiency, n 54
Hypercalcaemia, n 42
Other, n 32
Causes unrelated to MM, n (%) 6 (24) 7 (30)
Stroke, n 32
Myocardial infarction, n 02
Heart failure, n 10
Acute leukaemia and tumours, n 21
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Figure 2 Survival of patients with stage I multiple myeloma randomized to
be treated at disease progression according with the need of treatment
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Figure 3 Flow diagram of treatment of stage I multiple myeloma (MPH-P =
melphalan-prednisone; PTC-VCR-P = peptichemio-vincristine-prednisone;
CR = complete response; PR = partial response; SD = stable disease;
Prog = progression)Early or late treatment for stage I myeloma 1259
British Journal of Cancer (2000) 82(7), 1254–1260 © 2000 Cancer Research Campaign
chemotherapy are prerequisites for BMT (Bataille and
Harousseau, 1997; Riccardi et al, 1998). On the other hand,
several series (Fermand et al, 1993; Harousseau et al, 1995; Attal
et al, 1996; Marit et al, 1996) exclude just stage I MM from BMT,
due to their intrinsic good prognosis.
Delaying MPH-P could also reduce an increased occurrence of
second tumours possibly linked to the longlasting alkylating
therapy. This has been reported by Bergsagel (1988), although not
confirmed in this study, as well as in chronic lymphocytic
leukaemia patients treated with chlorambucil (Dighiero et al,
1998).
From Hjorth et al’s (1993) study and the present series, a
possible disadvantage of deferring therapy is that about 2–3% of
untreated patients experience vertebral compression. Although
this fact does not influence survival, untreated patients must be
well informed and promptly examined whenever clinical and/or
laboratory data suggest disease progression.
A more general point is that the practical importance of distin-
guishing the monoclonal gammopathies of unknown significance
(MGUS) from early MM is diminished, because treatment is to be
delayed until progression in both diseases. This is true despite the
fact that the two entities still maintain laboratory and, especially,
clinical differences. As a matter of fact, the high cut-off point of
20% BMPC we used to separate MGUS from stage I MM in
patients without bone disease discriminated two populations of
patients having different clinical disease courses. In fact, the rate
of malignant transformation and progression of MGUS to MM is
low and continuous over time. In our series, the 10% of 735
MGUS have experienced progression to MM at a median follow-
up of 5.8 years (unpublished data). The 30% of patients experience
it after 15 years from diagnosis (Kyle, 1993). On the contrary, the
progression of stage I MM occurred within 1–2 years in the
26–56% of patients (Dimopoulos et al, 1993; Hjorth et al, 1993;
Facon et al, 1995; present series). This prompts a closer follow-up
for stage I MM than for MGUS.
A question is that patients with stage I MM randomized to have
treatment delayed and who actually progressed and were treated
fared worse than those who had no disease progression and then
were untreated, despite no major clinical or laboratory differences
between the two groups were apparent. Certainly, patients who
require treatment due to disease progression have or acquire
increased biologic aggressiveness of a number of plasma cell
clones (for example, marked by aneuploidy) (Montecucco et al,
1984) and a number of them enter stage II and III disease. Against
these clones, MPH-P treatment is overall less effective, as indi-
cated by the shorter duration of response in the overall group of
stage I, II and III patients treated at progression than in stage I
patients treated just after diagnosis.
Then differences between plasma cell clones exist and have to
be searched, including, beside aneuploidy (Montecucco et al,
1984), high proliferative activity (Drewinko et al, 1981; Riccardi
et al, 1985), plasmablastic cytology (Riccardi et al, 1990), c-myc,
N-ras and K-ras oncogene mutations (Danova et al, 1990), and
CD19, CD28, CD36, LFA-1 and VLA-5 expression (Bataille and
Harousseau, 1997). An abnormal magnetic resonance imaging in
the bone marrow could also increase the risk of progression (Van
de Berg et al, 1996; Mariette et al, 1999).
As a conclusion, deferring therapy until disease progression does
not compromise survival duration in stage I MM. Hence, treatment
may be delayed at time of disease progression even if patients must
be well informed about risk, i.e. vertebral compression can occur
while deferring therapy. Because patients who have treatment
delayed and are treated at disease progression fare worse than those
who had no disease progression and are still untreated, biologic or
other disease features have to be searched for to identify these
subgroups of stage I MM patients.
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